Document Detail


Renal changes associated with cyclosporine in recent type I diabetes mellitus.
MedLine Citation:
PMID:  1889846     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of cyclosporine A treatment on arterial pressure and renal function were assessed in 11 young patients with type I diabetes of short duration. Cyclosporine was started at 7.5 mg/kg/day, progressively decreased to 6.3 mg/kg/day at 6 months, and then continued at a lower dose (4.1 mg/kg/day) for an additional 3 months in patients in whom remission of insulin dependency was obtained (n = 6). After 3 months of cyclosporine, a slight but significant increase in arterial pressure (+5.2 +/- 1.5 mm Hg), a rise in renal vascular resistance (approximately 20%), a decrease in glomerular filtration rate (approximately 25%), and a fall in filtration fraction were observed. Such changes were sustained after 6 and eventually 9 months of therapy. The decrease in glomerular filtration rate observed during cyclosporine treatment contrasted with the lack of change in simultaneously estimated creatinine clearance; in fact, the creatinine clearance/glomerular filtration ratio increased from 1.07 +/- 0.05% to 1.33 +/- 0.09% within 3 months of cyclosporine therapy, thus suggesting an enhanced tubular secretion of creatinine. Plasma renin activity and urinary excretion of kallikrein decreased significantly (approximately 50%), whereas plasma aldosterone concentration remained unaltered and plasma concentration of potassium increased during cyclosporine therapy. These changes were observed in the presence of a constant urinary excretion of sodium and potassium and a constant body weight. All parameters returned to pretreatment values within 3 months after cessation of cyclosporine. These results indicate that cyclosporine given for 6-9 months at a moderate dose causes a deleterious but reversible effect on arterial pressure and renal function in young diabetic patients.
Authors:
M Rodier; J Ribstein; C Parer-Richard; A Mimran
Related Documents :
22182436 - Serum holotranscobalamine, vitamin b12, folic acid and homocysteine levels in patients ...
21804276 - Elevated plasma levels of adropin in heart failure patients.
6419136 - Effect of demeclocycline on renal function and urinary prostaglandin e2 and kallikrein ...
22530656 - Comparison of salivary and plasma antioxidant levels in lichen planus patients and heal...
2137846 - Androgen excess in women with acne alone compared with women with acne and/or hirsutism.
2428856 - Prostaglandin d2 and histamine release in cold urticaria.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hypertension     Volume:  18     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:  1991 Sep 
Date Detail:
Created Date:  1991-10-11     Completed Date:  1991-10-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  334-40     Citation Subset:  IM    
Affiliation:
Department of Medicine and Endocrinology, Centre Hospitalier Universitaire, Montpellier, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Blood Pressure / drug effects
Cyclosporins / administration & dosage,  adverse effects*,  therapeutic use
Diabetes Mellitus, Type 1 / drug therapy*,  physiopathology
Humans
Kallikreins / urine
Kidney / drug effects*,  physiopathology
Proteinuria / urine
Renin-Angiotensin System / drug effects
Chemical
Reg. No./Substance:
0/Cyclosporins; EC 3.4.21.-/Kallikreins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence for a renomedullary vasodepressor system in rabbits and dogs.
Next Document:  Glucose tolerance and insulin action in rats with renovascular hypertension.